(AP) — BioSante Pharmaceuticals Inc. said a clinical study indicates its drug LibiGel does not increase heart problems and death in high-risk women. LibiGel is a testosterone gel applied to the skin, and BioSante is testing it as a treatment for sexual dysfunction in women. It is running ...
Copyright CRAIN - Crain's
